Arrowhead Pharmaceuticals, Inc.
NASDAQArrowhead Pharmaceuticals heads into the final days of Q2 with shorts unwinding rapidly, options skewing heavily toward calls, and the Street largely constructive ahead of an August earnings catalyst. The short side of the trade has compressed sharply this month. Short interest dropped 11% in a single week to around 7.9% of free float — and is down more than 20% from its May highs…
ARWR put/call ratio plummets to 0.3783, nearly 4 standard deviations below the 20-day mean of 0.5515, signaling aggressive call buying and the lowest PCR in 52 weeks.
Snapshot as of 11 Jul 2026
Arrowhead Pharmaceuticals heads into the final days of Q2 with shorts unwinding rapidly, options skewing heavily toward calls, and the Street largely constructive ahead of an August earnings catalyst. The short side of…
Arrowhead Pharmaceuticals enters the back half of June with short sellers quietly retreating and the Street turning more constructive — a combination that has helped the stock add 4.4% on the week to $76.55, even as it…
Arrowhead Pharmaceuticals enters late May with its strongest Street reception in months — yet options traders are quietly buying more protection than usual, creating a rare split between institutional conviction and…
Arrowhead Pharmaceuticals heads into mid-May with a striking divergence: the Street is growing more constructive, yet short sellers are rebuilding positions at their fastest weekly pace in over a month. Short interest…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ARWR — free to start on ORTEX.
Sign up for free →Open ARWR on ORTEX